Norcantharidin overcomes vemurafenib resistance in melanoma by inhibiting pentose phosphate pathway and lipogenesis via downregulating the mTOR pathway

• Автори: Lei Wang (Автор), Wuxiyar Otkur (Автор), Aman Wang (Автор), Wen Wang (Автор), Yitong Lyu (Автор), Lei Fang (Автор), Xiu Shan (Автор), Mingzhou Song (Автор), Yan Feng (Автор), Yi Zhao (Автор), Hai-Long Piao (Автор), Huan Qi (Автор), Ji-Wei Liu (Автор)
• Формат: Книга
• Опубліковано: Frontiers Media S.A., 2022-08-01T00:00:00Z.
• Предмети: article
• Онлайн доступ: Connect to this object online.

Melanoma is the most aggressive type of skin cancer with a high incidence and low survival rate. More than half of melanomas present the activating BRAF mutations, along which V600E mutant represents 70%-90%. Vemurafenib (Vem) is an FDA-approved small-molecule kinase inhibitor that selectively targe...